Recently, Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial of its investigational therapy reproxalap eye drops in patients with dry eye disease
Both endpoints of the trial showed that patients who received reproxalap reported significantly lower scores for both ocular discomfort (p=0.
002) and itching symptoms (p=0.
01) compared to the active drug control group
In patients with dry eye, proinflammatory reactive aldehyde species (RASP) may contribute to ocular inflammation and changes in tear lipid composition
Reproxalap is a novel small molecule RASP inhibitor, which can reduce the level of RASP and achieve the effect of inhibiting inflammation and relieving symptoms
The therapy has been evaluated in more than 1,500 patients
It is currently being evaluated in a pivotal Phase 3 clinical trial, with results expected by the middle of this year
The double-blind, crossover, single-center Phase 2 clinical trial enrolled 56 patients with dry eye disease and evaluated the improvement in symptoms of 0.
25% reproxalap compared to the approved prescription drug
No safety signals were observed in the trial, and no treatment-related discontinuations or drug-related moderate or serious adverse events occurred
The most common adverse event in both treatment groups was mild instillation site discomfort
Image source: Reference 
Dry eye is one of the most common chronic eye diseases, affecting the quality of life of millions of people, causing persistent stinging, burning, sensitivity to light, blurred vision and eye strain
Damage to the tear film is one of the main causes of dry eye
The human tear film contains more than 1,500 different proteins, including growth factors and antibodies, as well as numerous classes of lipids and mucins that protect and lubricate the eye
At present, the main treatment method for dry eye is the use of artificial tears, but most patients fail to obtain satisfactory treatment results
 Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®.
Retrieved January 11, 2022, from https://ir.